Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MDK | P21741 | 4/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.37 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18333324 | 0.95 | MAPK1 (0.41) | MAPK1MDKLGALS3LGALS8LGALS4 | |
| SCHEMBL12673872 | 0.93 | MAPK1 (0.45) | MAPK1MDKLGALS3LGALS8LGALS4 | |
| SCHEMBL18333352 | 0.89 | MDK (0.42) | MAPK1MDKLGALS3B4GALT1MEN1 | |
| SCHEMBL24259909 | 0.89 | MAPK1 (0.49) | MAPK1MDKLGALS3LGALS8LGALS4 | |
| SCHEMBL18333126 | 0.88 | MDK (0.41) | MAPK1MDKLGALS3LGALS8LGALS4 | |
| SCHEMBL16359388 | 0.88 | MAPK1 (0.44) | MAPK1MDKLGALS3LGALS8LGALS4 | |
| SCHEMBL15369067 | 0.88 | MAPK1 (0.44) | MAPK1MDKLGALS3LGALS8LGALS4 | |
| SCHEMBL21190108 | 0.86 | MAPK1 (0.58) | MAPK1MDKLGALS3LGALS8LGALS4 | |
| SCHEMBL27224811 | 0.86 | MAPK1 (0.49) | MAPK1MDKLGALS3LGALS8LGALS4 | |
| SCHEMBL15369069 | 0.86 | MDK (0.43) | MAPK1MDKLGALS3LGALS8LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367687-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367687-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, LNPEP, BST2 | MAPK1 4706/4885MDK 1849/4885LGALS3 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.